Interestingly, it was suggested that CCR5 inhibition reduces infiltration of both innate and adaptive immune cells, which leads to reduced inflammation in the colon during colitis and CRC (23, 33, 34), although CCR5 might interact with other ligands, based on the comparable levels of expression of CCL3. This evidence concerns the gene CCL3 and colorectal carcinoma.